Cardiovascular disease in postmenopausal women

Maturitas

Volumn 30, Issue 1, 1998, Pages 11-18

  Samsioe, Göran ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardioprotection; Cardiovascular disease; Myocardial infarction; Oestrogens; Risk factors

Indexed keywords

ESTROGEN; FIBRINOLYTIC AGENT; MORPHINE;

ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; BYPASS SURGERY; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; COLLAGEN DISEASE; CORONARY ARTERY SPASM; DIABETES MELLITUS; ELECTROCARDIOGRAM; FEMALE; HEART INFARCTION; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MALE; MORTALITY; POSTMENOPAUSE; RAYNAUD PHENOMENON; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING; SYNDROME X; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0032552582     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(98)00054-1     Document Type: Article

References (38)

1. Schenck-Gustafsson K, Svane B, Kjellström B, Orth-Gomer K. Coronary angiogram and other baseline characteristics in the Stockholm study in women with coronary entery disease. In: 3rd International Conference on Preventive Cardiology, 27/6-1/7, 1993, Oslo.
2. Schenck-Gustafsson K. Risk factors for cardiovascular disease in women: assessment and management. Eur Heart J. 17:1996;35-39.
3. Hammar N, Ivert T, Larsen F, Sandberg E. Early and late mortality after coronary by-pass surgery in women compared to men during 1980-89 in Stockholm, Sweden. Eur Heart J 1996;25(8):(abstract 2759).
4. Rosano G.M.C., Collins P., Kaski J.C.et al. Syndrome X in women is associated with estrogen deficiency. Eur Heart J. 16:1995;610-614.
5. Hong MK, Romm PA, Reagan K, et al. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol 1992;69:176-78.
6. Sullivan J.M., Van der Zwaag R., Hughes J.P. Estrogen replacement and coronary artery disease. Arch Intern Med. 150:1990;2557-2562.
7. Gruchov H.W., Anderson A.J., Barboriak J.J.et al. Postmenopausal use of estrogen and coronary arteriosclerosis. Am Heart J. 115:1988;954-963.
8. McFarland K.J., Bonifac M.E., Homung C.A.et al. Risk factors and non contraceptive estrogen use in women with and without coronary disease. Am Heart J. 117:1989;1209-1214.
9. Samsioe G. Lipid profiles in estrogen users. In: Sitruk-Ware R, Utian W, editors. The Menopause and Hormonal Replacement Therapy. New York: Marcel Deckker, 1991:181-200.
10. Crook D., Cust Mp, Gangar K.F.et al. Comparison of transdermal and oral estrogen/progestin replacement therapy: Effects on serum lipids and lipoproteins. Am J Obstet Gynecol. 166:1992;950-953.
11. Melin T., Qi C., Bengtsson-Olivecrona G., Åkesson B., Nilsson Å. Hydrolysis of chylomicron polyenoic fatty acid esters with lipoprotein lipase and hepatic lipase. Biochim Biophys Acta. 1075:1991;259-266.
12. Beisiegel U. Receptors for triglyceride-rich lipoproteins and their role in lipoprotein metabolism. Curr Opin Lipidol. 6:1995;117-122.
13. Samsioe G., Balsell G., Åberg A., Sandin K. Transdermal oestradiol plus medroxyprogesteron acetates lower cholesterol in moderately hypercholesterolemic women. Maturitas (Abstract). 27(Suppl):1966;65.
14. Tonstad S., Ose L., Görbitz C.et al. Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolaemia among postmenopausal women. J Int Med. 238:1995;39-47.
15. Tikkanen M.J., Nikkilä E.A., Variainen E. Natural oestrogen as an effective treatment for type-II hyperlipoproteinaemia in postmenopausal women. Lancet. ii:1978;490-492.
16. Darling G.M., Johns J.A., McCloud P.I., Davis S.R. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. New Engl J Med. 337:1997;595-601.
17. Sirtori CR, Soma MR. HRT and correction of lipoprotein disorders. In: Crosignani PR et al., editors. Women's Health in Menopause. Dordrecht: Kluwer, 1994:159-69.
18. Winkler U.H. Hormone replacement therapy and hemostasis: principles of a complex interaction. Maturitas. 24:1996;131-145.
19. Samsioe G. Coagulation and anticoagulation effects of contraceptive steroids. Am J Obstet Gynecol. 170:1994;1523-1527.
20. Grodstein F., Stampfer M.J., Goldhaber S.Z.et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 348:1996;983-987.
21. Daly E., Vessey M.P., Hawkins M.M.et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 348:1996;977-980.
22. Jick H., Derby L.E., Myers M.W.et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 348:1996;981-983.
23. Pérez Gutthann S., García Rodríguez L.A., Castellsague J.et al. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Br Med J. 314:1997;796-800.
24. Nabulsi A.A., Folsom A.R., White A.et al. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. The atherosclerosis risk in Communities Study Investigators. New Engl J Med. 328:1993;1069-1075.
25. Lindoff C., Petersson J.F., Lecander I.et al. Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease. Maturitas. 24:1996;43-50.
26. Gilabert J., Estellés A., Cano A.et al. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol. 173:1995;1849-1854.
27. Larsson-Cohn U., Wallentin L. Metabolic and hormonal effects of postmenopausal oestrogen replacement treatment. Acta Endocrinol. 86:1997;583-596.
28. Spellacy W., Buhi W., Birk S. Effect of estrogen treatment for one year on carbohydrate and lipid metabolism. Am J Obstet Gynecol. 131:1978;87-90.
29. Godsland I., Gangar K., Walton C.et al. Insulin resistance, secretion and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism. 42:1993;846-853.
30. Lobo R.A. Estrogen replacement therapy and hypertension. Postgrad Med. 14(September):1987;48-54.
31. Akkad A.A., Halligan A.W.F., Abrams K., Al-Azzawi F. Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. Obstet Gynecol. 89:1997;97-103.
32. Proudler A.J., Hasib Ahmed Al, Crook D.et al. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet. 346:1995;89-90.
33. Collins P., Rosano G.M., Jiang C.et al. Cardiovascular protection by oestrogen - a calcium antagonist effect? Lancet. 341:1993;1264-1265.
34. Collins P., Rosano Gm, Sarrel P.M.et al. 17β-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation. 92:1995;24-30.
35. Pasqualini C., Leviel V., Guibert B.et al. Inhibitory actions of acute estradiol treatment on the activity and quantity of tyrosine hydroxylase in the median eminence of varioectomized rats. J Neuroendocrinol. 3:1991;575-580.
36. Diaz M.N., Frei B., Vita J.A., Keaney J.F. Jr. Antioxidants and atherosclerotic heart disease. New Engl J Med. 337:1997;408-416.
37. Weigratz B., Hertwig B., Jung-Hoffmann C., Kuhl H. Inhibition of low-density lipoprotein oxidation in vitro and ex vivo by several estrogens and oral contraceptives. Gynecol Endocrinol. 10(Suppl 2):1996;149-152.
38. Schröder J., Dören M., Schneider B., Oettl M. Are the antioxidative effects on 17β-oestradiol modified by concomitant administration of a progestogen? Maturitas. 25:1996;133-140.